These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36276084)

  • 1. Outcomes with mismatched unrelated donor allogeneic hematopoietic stem cell transplantation in adults: A systematic review and meta-analysis.
    Mushtaq MU; Shahzad M; Tariq E; Iqbal Q; Chaudhary SG; Zafar MU; Anwar I; Ahmed N; Bansal R; Singh AK; Abhyankar SH; Callander NS; Hematti P; McGuirk JP
    Front Oncol; 2022; 12():1005042. PubMed ID: 36276084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
    Shahzad M; Siddiqui RS; Anwar I; Chaudhary SG; Ali T; Naseem M; Ahmed TF; Ahmed Z; Khurana S; Ahmed N; Balusu R; Singh AK; Hematti P; Callander NS; Abhyankar SH; McGuirk JP; Mushtaq MU
    Transplant Cell Ther; 2021 Oct; 27(10):877.e1-877.e8. PubMed ID: 34284148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Who Is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA-Mismatched Haploidentical Relative or an Older Fully HLA-Matched Sibling or Unrelated Donor?
    Karam E; Laporte J; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A; Solh MM
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):2054-2060. PubMed ID: 31173900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of natural killer cells on outcomes after allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis.
    Mushtaq MU; Shahzad M; Shah AY; Chaudhary SG; Zafar MU; Anwar I; Neupane K; Khalid A; Ahmed N; Bansal R; Balusu R; Singh AK; Abhyankar SH; Callander NS; Hematti P; McGuirk JP
    Front Immunol; 2022; 13():1005031. PubMed ID: 36263054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haploidentical Transplantation with Post-Transplant Cyclophosphamide versus Unrelated Donor Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
    Arcuri LJ; Aguiar MTM; Ribeiro AAF; Pacheco AGF
    Biol Blood Marrow Transplant; 2019 Dec; 25(12):2422-2430. PubMed ID: 31386903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis.
    Shouval R; Fein JA; Labopin M; Kröger N; Duarte RF; Bader P; Chabannon C; Kuball J; Basak GW; Dufour C; Galimard JE; Polge E; Lankester A; Montoto S; Snowden JA; Styczynski J; Yakoub-Agha I; Mohty M; Nagler A
    Lancet Haematol; 2019 Nov; 6(11):e573-e584. PubMed ID: 31477550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
    Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of Haploidentical Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts in Pediatric Patients with Hematologic Malignancies: A Single-Center Analysis.
    Srinivasan A; Raffa E; Wall DA; Schechter T; Ali M; Chopra Y; Kung R; Chiang KY; Krueger J
    Transplant Cell Ther; 2022 Mar; 28(3):158.e1-158.e9. PubMed ID: 34838785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single Antigen-Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors.
    Jorge AS; Suárez-Lledó M; Pereira A; Gutierrez G; Fernández-Avilés F; Rosiñol L; Llobet N; Solano T; Urbano-Ispízua Á; Rovira M; Martínez C
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1196-1202. PubMed ID: 29410343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-Transplantation Cyclophosphamide-Based Haploidentical versus Matched Unrelated Donor Peripheral Blood Hematopoietic Stem Cell Transplantation Using Myeloablative Targeted Busulfan-Based Conditioning for Pediatric Acute Leukemia.
    Hong KT; Park HJ; Kim BK; An HY; Choi JY; Kang HJ
    Transplant Cell Ther; 2022 Apr; 28(4):195.e1-195.e7. PubMed ID: 35021131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes in Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia.
    Cancio M; Hebert K; Kim S; Aljurf M; Olson T; Anderson E; Burroughs L; Vatsayan A; Myers K; Hashem H; Hanna R; Horn B; Prestidge T; Boelens JJ; Boulad F; Eapen M
    Transplant Cell Ther; 2022 Feb; 28(2):101.e1-101.e6. PubMed ID: 34670170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.
    Koreth J; Stevenson KE; Kim HT; McDonough SM; Bindra B; Armand P; Ho VT; Cutler C; Blazar BR; Antin JH; Soiffer RJ; Ritz J; Alyea EP
    J Clin Oncol; 2012 Sep; 30(26):3202-8. PubMed ID: 22869883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission.
    Konuma T; Kanda J; Yamasaki S; Harada K; Shimomura Y; Terakura S; Mizuno S; Uchida N; Tanaka M; Doki N; Ozawa Y; Nakamae H; Sawa M; Matsuoka KI; Morishige S; Maruyama Y; Ikegame K; Kimura T; Kanda Y; Ichinohe T; Atsuta Y; Yanada M
    Transplant Cell Ther; 2021 Apr; 27(4):334.e1-334.e11. PubMed ID: 33836881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study.
    Eapen M; Brazauskas R; Walters MC; Bernaudin F; Bo-Subait K; Fitzhugh CD; Hankins JS; Kanter J; Meerpohl JJ; Bolaños-Meade J; Panepinto JA; Rondelli D; Shenoy S; Williamson J; Woolford TL; Gluckman E; Wagner JE; Tisdale JF
    Lancet Haematol; 2019 Nov; 6(11):e585-e596. PubMed ID: 31495699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allelic HLA Matching and Pair Origin Are Favorable Prognostic Factors for Unrelated Hematopoietic Stem Cell Transplantation in Neoplastic Hematologic Diseases: An Italian Analysis by the Gruppo Italiano Trapianto di Cellule Staminali e Terapie Cellulari, Italian Bone Marrow Donor Registry, and Associazione Italiana di Immunogenetica e Biologia dei Trapianti.
    Picardi A; Sacchi N; Miotti V; Lorentino F; Oldani E; Rambaldi A; Sessa M; Bruno B; Cerno M; Vago L; Bernasconi P; Arcese W; Benedetti F; Pioltelli P; Russo D; Farina L; Fagioli F; Guidi S; Saporiti G; Zallio F; Chiusolo P; Borghero C; Papalinetti G; La Rocca U; Milone G; Lamparelli T; Carella AM; Luppi M; Olivieri A; Martino M; Carluccio P; Celeghini I; Andreani M; Gallina AM; Patriarca F; Pollichieni S; Mammoliti S; Miccichè S; Mangione I; Ciceri F; Bonifazi F
    Transplant Cell Ther; 2021 May; 27(5):406.e1-406.e11. PubMed ID: 33965179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic Stem Cell Transplantation from HLA-Mismatched Donors for Pediatric Patients with Acute Lymphoblastic Leukemia Treated According to the 2003 BFM and 2007 International BFM Studies: Impact of Disease Risk on Outcomes.
    Dalle JH; Balduzzi A; Bader P; Lankester A; Yaniv I; Wachowiak J; Pieczonka A; Bierings M; Yesilipek A; Sedlaçek P; Ifversen M; Sufliarska S; Toporski J; Glogova E; Poetschger U; Peters C
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1848-1855. PubMed ID: 29772352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis.
    Shahzad M; Tariq E; Chaudhary SG; Anwar I; Iqbal Q; Fatima H; Abdelhakim H; Ahmed N; Balusu R; Hematti P; Singh AK; McGuirk JP; Mushtaq MU
    Leuk Lymphoma; 2022 Dec; 63(14):3409-3417. PubMed ID: 36107118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloablative Versus Reduced-Intensity Conditioning With Fludarabine/Busulfan for Myelodysplastic Syndrome: A Propensity Score-Matched Analysis.
    Kurosawa S; Shimomura Y; Itonaga H; Najima Y; Kobayashi T; Ozawa Y; Kanda Y; Kako S; Kawakita T; Matsuoka KI; Maruyama Y; Ota S; Nakazawa H; Imada K; Kimura T; Kanda J; Fukuda T; Atsuta Y; Ishiyama K
    Transplant Cell Ther; 2022 Jun; 28(6):323.e1-323.e9. PubMed ID: 35296446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparable outcome after single-antigen-mismatched versus matched unrelated donor haematopoietic cell transplantation.
    Rockstroh A; Al-Ali HK; Lange T; Pönisch W; Krahl R; Cross M; Behre G; Niederwieser D; Pfrepper C
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2193-203. PubMed ID: 26129640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.